

BRIAN SANDOVAL
Governor

RICHARD WHITLEY, MS
Director



MARTA JENSEN
Acting Administrator

DEPARTMENT OF HEALTH AND HUMAN SERVICES
DIVISION OF HEALTH CARE FINANCING AND POLICY
1100 East William Street, Suite 101
Carson City, Nevada 89701
Telephone (775) 684-3676 • Fax (775) 687-3893
<http://dhcfp.nv.gov>

May 2, 2017

Inter-Tribal Council of Nevada
Executive Board President
Vinton Hawley, Chairman
Pyramid Lake Paiute Tribe
P.O. Box 256
Nixon, NV 89424

Dear Tribal Members:

In accordance with established consultation guidelines, the Division of Health Care Financing and Policy (DHCFP) is notifying Nevada tribes of the following proposed change in policy:

Revisions to Medicaid Services Manual, Chapter 1200, Appendix A were made to reflect approved actions by the Drug Use Review (DUR) Board at the October 26, 2016 and January 26, 2017 meetings.

On October 26, 2016, new prior authorization criteria were approved for Epclusa® (sofosbuvir/velpatasvir).

On January 26, 2017, revised prior authorization criteria was approved for Buprenorphine/Naloxone (Suboxone®/Subutex®), Orkambi® (lumacaftor/ivacaftor) and medications for recipients on hospice. Prior authorization criteria was removed for Byetta® (exenatide), Bydureon® (exenatide extended-release) and Victoza® (liraglutide). Criteria was revised for evaluating recipients for the Lock-in Program.

There will be no fiscal impact for the tribes due to these changes.

If you would like a consultation regarding this new policy, please contact Colleen McLachlan at (775) 684-3722 who will schedule a meeting. We would appreciate a reply within 30 days from the date of this letter. If we do not hear from you within this time, we will consider this an indication that no consultation is requested.

Sincerely,



Lynne Foster
Chief of Division Compliance

Cc: Shannon Sprout, Deputy Administrator
Duane Young, Chief, Behavioral Health and Pharmacy
Mary Griffith, RN, SSPS III, Policy Development and Program Management